GEOGRAPHIC ATROPHY

This study tests an experimental implant placed under the retina to treat advanced dry age-related macular degeneration (geographic atrophy). About 24 people aged 55-90 will take part, with most receiving the implant and a few receiving a sham procedure. The goal is to see if the…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of ABBV-6628 or an approved treatment (SYFOVRE) to …

This early-stage trial tests if replacing damaged eye cells with lab-grown stem cells can help people with dry age-related macular degeneration and geographic atrophy. About 20 adults aged 55 and older will receive a transplant of their own reprogrammed cells into one eye. The ma…

This study is for people in Japan aged 40 and older with geographic atrophy, a form of age-related macular degeneration that causes vision loss. The goal is to check the safety of a monthly eye injection called ASP3021 over 12 months. About 20 participants will receive the inject…

This study tests a new drug called VOY-101 in 60 people aged 60 and older with advanced dry age-related macular degeneration (AMD), a condition that causes blind spots. The goal is to see if the drug is safe and can slow the growth of these spots and preserve vision. Participants…

This study tests a cell therapy called OpRegen in 60 people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The goal is to see if surgeons can safely deliver the cells to the right spot in the eye and if the treatment can im…

This study tests a single injection of SAR446597 into the eye for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. About 104 adults aged 60 and older will join to see if the treatment is safe and can slow vision loss o…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with non-foveal geographic atrophy will take the dr…

This study follows 1,000 people with geographic atrophy (an advanced form of age-related macular degeneration) who are already being treated with the drug Izervay. Researchers will collect information from medical records and patient surveys over up to 5 years to see how the drug…

This study uses a special camera to take extremely detailed pictures of the retina, the light-sensitive layer at the back of the eye. Researchers want to see how individual cells differ between healthy eyes and eyes with diseases like Stargardt's or age-related macular degenerati…

This study tests two imaging methods—central microperimetry and radial OCT—to see if they can more accurately measure the progression of geographic atrophy, a form of age-related macular degeneration that can lead to vision loss. Researchers will follow 80 participants aged 55 an…